Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ALT 11.11.2024

Full Press ReleaseSEC FilingsOur ALT Tweets

About Gravity Analytica

Recent News

  • 01.07.2025 - Annabel Samimy
  • 12.19.2024 - Altimmune Added to Nasdaq Biotechnology Index
  • 12.06.2024 - 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

Recent Filings

  • 01.03.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.11.2024 - 8-K Current report
PDF Version

GAITHERSBURG, Md.,Nov. 11, 2024(GLOBE NEWSWIRE) --Altimmune, Inc.(Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of Directors granted equity awards under Altimmune’s 2018 Inducement Grant Plan, as a material inducement to employGregory Weaveras Altimmune’s Chief Financial Officer effectiveNovember 11, 2024. The equity awards were approved onNovember 6, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).

Mr. Weaverreceived, in the aggregate, options to purchase 225,000 shares of Altimmune’s common stock, and 75,000 restricted stock units (“RSUs”). The options will have an exercise price equal to the closing price of Altimmune’s common stock onNovember 11, 2024(the “Grant Date”). Based on the closing price Altimmune’s common stock onNovember 8, 2024, Altimmune would issue approximately 172,920 options as inducement awards under its 2018 Inducement Grant Plan, and the balance as incentive stock options under its 2017 Omnibus Incentive Plan. The final allocation of options between the 2018 Inducement Grant Plan and 2017 Omnibus Plan are subject to adjustment based on the closing price of Altimmune’s common stock on the Grant Date. One-fourth of the shares underlying the options will vest on the one-year anniversary of the Grant Date and thereafter 1/36th of the shares underlying the options will vest monthly, such that the shares underlying the options will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to Mr. Weaver’s continued employment with Altimmune on such vesting dates.

One-fourth of the RSUs will vest on the one-year anniversary of the Grant Date and thereafter the RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to Mr. Weaver’s continued employment with Altimmune on such vesting dates.

AboutAltimmuneAltimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information on Altimmune, please visitwww.altimmune.com.

Follow @Altimmune, Inc. onLinkedInFollow @AltimmuneInc onTwitter

Company Contact:Vipin GargPresident and Chief Executive OfficerPhone: 240-654-1450ir@altimmune.com

Investor Contacts:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com

Julia WeilmanBurns McClellanPhone: 646-732-4443jweilman@burnsmc.com

Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com

This press release was published by a CLEAR® Verified individual.

Primary Logo

Source: Altimmune, Inc

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com